Share This
Create Your Own Business Intelligence Website
Input the stock code or the company name     Search  

<300147.CN> - Xiangxue Pharmaceutical Co., Ltd.

 
 Basic Datum
Company name 资产收益 每股收益 每股资产 收入增长 利润增长
XXZY 1.09% 0.06 5.53 29.76% 14.82%
 
Company name 价位 五日表现 五日换手 十日表现 十日换手
XXZY 9.45 28.31% 77.54% 19.33% 121.77%
 
所属板块: 创业板 医药 广东 生物医药
 
 
 Related news  
5月16日,香雪制藥(300147)(SZ300147,股價3.98元,市值26.32億元)收到了來自深交所的年報問詢函。2023年,香雪制藥虧損3.89億元,過去三年累計虧損約16億元,並且審計機構對公司財報出具了保留意見的審計報告,主要因會計師無法對部分固定資產和在建工程余額的准確性獲取充分、適當的審計證據,也無法確定是否存在與之相關的關聯方資金占用情形
≫More
 
 
 
 
 
 Top Gain / Loss Show All Charts 
 
 Value
Name Updated Value Change Change %
XXZY 05-13 15:00 9.45  0.04  0.43%
≫More
 
 
More Topics:
| Real Est HKConstructionReal Est ChinaRentals | REITs
AgriEnviro | fertilizer producersWater | Util
HK Banks | China Banks | Insure | China Finance | Brokers
Consumer | Food | SupermarketDiaryEducation
merchant | Garment | HK Apparel | Sports
Appl | Auto | jewel | Beauty | HK retail
Shipping | Shipbuilding | Harbour | Highways | Airlines | logistics | Expo | Textile
Paper | Resource | Rare Earths | Steel | Gold mine | Mach
Petro | Electricity | Nuclear power | New Energy | gas | coal
Infra | Railway | Build Mat | Cement
China IT | Communication
GamblingChina LotterymediafilmDrugs
  HK Housing Market | Real Estate Market | | |
| | | HK Stock | Stock Trend | capital flow |
A Shares | ETF | IPO | |
Gold | Gold Jew | Oil | Commodity | G20 | Top 500
USD | GBD | EURO | Swiss franc | AUD | NZD | CAD | YEN | RMB | Korean Won | Taiwan Dollar (TWD)
iBond | Emerging markets
Lang | Andy Xie | Simon Ting | Law Ka-Chung | LiuDongliang | XieXuren | FanGang | Mobius | BillGross | Roubini | Faber
Financial and political policy | Central Bank Monetary Policy | Social Security Fund
| | | |

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.